{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-064106","form_type":"8-K","ticker":"BNBX","cik":"0000744452","company_name":"BNB PLUS CORP.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.143360+00:00","generated_at":"2026-05-18T15:08:48.686836+00:00","sec_items":["2.05","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Applied DNA restructures to focus on LineaRx; cuts 27% of staff, shuts clinical lab","bullets":["Workforce reduction of 27% (projected 23% payroll cut); ceases operations at Applied DNA Clinical Labs.","One-time charges of ~$300k; majority of costs expected by Sept 30, 2025.","CEO Judy Murrah takes 15% salary reduction to $340k/year.","Company ends May 2025 with ~$4.8M cash; cumulative headcount reduction of 39% since Dec 2024.","Restructuring positions LineaRx synthetic DNA manufacturing as sole focus."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-064106","json":"https://secwatch.observer/filing/0001104659-25-064106.json","markdown":"https://secwatch.observer/filing/0001104659-25-064106.md","text":"https://secwatch.observer/filing/0001104659-25-064106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/0001104659-25-064106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/tm2519488d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T15:08:48.686836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28a90aff2ad3e9e27653301338b2e036873b8a32","claim":"BNB PLUS CORP. announced a restructuring with charges of approximately $300 thousand in one-time charges affecting Applied DNA Clinical Labs (ADCL); company-wide workforce reduction (approximately 27% of headcount).","evidence_excerpt":"Company’s former Chairman and Chief Executive Officer. The projected annual payroll savings is expected to be partially offset by approximately three hundred thousand dollars ($300,000) in one-time charges related to the workforce reduction and ceasing of operations at ADCL, primarily for separation benefits. The Company expects to incur the majority of","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/744452/000110465925064106/0001104659-25-064106-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $300 thousand in one-time charges"},{"label":"Affected area","value":"Applied DNA Clinical Labs (ADCL); company-wide workforce reduction"},{"label":"Headcount","value":"approximately 27% of headcount"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}